Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
Figure 2
Evidence of structure of GI AEs for MTC meta-analysis. The numbers along the link lines indicate the number of trials or pairs of trial arms. Lines connect the interventions that have been studied in head-to-head (direct) comparisons in the eligible RCTs. The width of the lines represents the cumulative number of RCTs for each comparison, and the size of every node is proportional to the number of randomized participants (sample size). CT: conventional treatment. EX5BID: exenatide 5 μg twice daily; EX10BID: exenatide 10 μg twice daily; EX2QW: exenatide 2 mg once weekly; LIR0.6: liraglutide 0.6 mg once daily; LIR1.2: liraglutide 1.2 mg once daily; LIR1.8: liraglutide 1.8 mg once daily.
